Med. praxi. 2012;9(11):445-450

Menopause - treatment of complaints

doc.MUDr.Taťána Rešlová, CSc.
Porodnická a gynekologická klinika LF UK a FN Hradec Králové

Cessation of ovarian function is associated with a significant reduction in plasma estrogen concentration that results in the development

of more or less serious somatic, functional, and mental changes. Early symptoms of estrogen deficiency in postmenopausal women

are most effectively managed with hormone replacement therapy. This year, ten years have elapsed since the publication of the initial

results of the Women's Health Initiative study that substantially altered the approach of both physicians and the public to influencing

the sequelae of menopause. The subsequent analyses and new findings became the basis for revising the decision-making process in

prescribing ET/EPT and recommending alternative means. Initiation of ET/EPT in the peri- and early postmenopausal periods with the

lowest possible effective doses minimizes adverse events and ensures a preponderance of benefit over risk. In the case of contraindications,

safer, but less effective nonhormonal alternatives can be recommended. Hormone replacement is not suitable for the prevention

and treatment of late sequelae of menopause.

Keywords: menopause, estrogen deficiency, hormone replacement therapy

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rešlová T. Menopause - treatment of complaints. Med. praxi. 2012;9(11):445-450.
Download citation

References

  1. Eddy D. Designing a practice policy: standards, guidelines, and options. JAMA, 1990; 263: 3077-3084. Go to original source... Go to PubMed...
  2. The North American Menopause Society develops consensus opinions. Menopause 1998; 5: 67-68. Go to PubMed...
  3. Teede HJ, Vincent A. Hormone therapy. Where are we now? Australian Family Physician 2011; 40: 280-285. Go to PubMed...
  4. Sturdee DW. The menopausal hot flush-Anything new? Maturitas 2008; 60: 42-49. Go to original source... Go to PubMed...
  5. Andricoula M, Prelevic G. Menopausal hot flashes revisited. Climacteric 2009; 12: 3-15. Go to original source... Go to PubMed...
  6. Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health 2007; 10: 247-257. Go to original source... Go to PubMed...
  7. Dormire SL, Bongiovani R. Norepinephrine activity, as measured by MHPG, is associated with menopausal hot flushes. Climacteric 2008; 11: 397-403. Go to original source... Go to PubMed...
  8. Freedman RR. Hot flashes: behavioral treatments, mechanisms, and relation to sleep. JAMA, 2005; 118: 1245-1305. Go to original source... Go to PubMed...
  9. Hall E, Frey BN, Soares CN. Non hormonal treatment strategies for vasomotor symptom: a critical review. Drugs, 2011; 71: 287-304. Go to original source... Go to PubMed...
  10. Pachman DR, Jones JM, Loprinzi ChL. Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions. International J of Womens Health. 2010; 2: 123-135. Go to original source...
  11. Lipov EG, Lipov S, Joshi JR, et al. Stellate ganglion block may relieve hot flashes by interrupting the sympathetic nervous system. Medical Hypotheses 2007; 69: 758-763. Go to original source... Go to PubMed...
  12. Lipov EG, Joshi JR, Sanders S, Slavin KV. A unifying theory linking the prolonged efficacy of the stellate ganglion block for the treatment of chronic regional pain syndrome (CRPS), hot flashes, and posttraumatic stress disorder (PTSD). Medical Hypotheses 2009; 72: 657-661. Go to original source... Go to PubMed...
  13. Pachman DR, Barton D, Carns PE, et al. Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. Support Care Cancer, 2010. Go to original source...
  14. Grady D. Postmenopausal hormones-therapy for symptoms only. N Engl J Med, 2003; 348: 183-187. Go to original source... Go to PubMed...
  15. Santen RJ, Allred DC, Ardoiu SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95: 1-66. Go to original source... Go to PubMed...
  16. Stuenkel CA, Gass MLS, Manson JE. A decade after the Womens health initiative-the experts do agree. Fertil Steril 2012; 98: 313-314. Go to original source... Go to PubMed...
  17. Osmanagaoglu MA, Osmanagaoglu S, Osmanagaoglu T, et al. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors and bone mineral density in overweight and obese postmenopausal women. Fertil Steril 2005; 84: 384-393. Go to original source... Go to PubMed...
  18. The North American Menopause Society.: The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012; 19: 257-271. Go to original source... Go to PubMed...
  19. MacLennan AH, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2001, CD002978. Go to original source...
  20. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev, 2006; 18: CD001500. Go to original source... Go to PubMed...
  21. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thrombembolic disease. The heart and estrogen/progestin replacement study. Ann Intern Med, 2000; 132: 689-696. Go to original source... Go to PubMed...
  22. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA, 304: 1684-1692. Go to original source... Go to PubMed...
  23. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with difference hormone replacement therapies results from the E3N cohort study. Breast cancer Res Treat, 2008; 107: 103-111. Go to original source... Go to PubMed...
  24. Justenhoven Ch, Obazee O, Brauch H. The pharmacogenomics of sex hormone metabolism: breast cancer risk in menopausal hormone therapy. Pharmacogenomics 2012; 13: 659-675. Go to original source... Go to PubMed...
  25. Kokolus KM, Hong CC, Repasky EA. Feeling to hot or cold after breast cancer: is it just a nuisance or potentially important prognostic factor? Int J Hypertermia 2010; 26: 662-680. Go to original source... Go to PubMed...
  26. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009; 113: 65-73. Go to original source... Go to PubMed...
  27. Hamilton TR, Rettberg JR, Mao Z, et al. Hippocampal responsiveness to 17?-estradiol and equol after long-term ovariectomy: implication for a therapeutic window of opportunity. Brain Res, 2011; 16: 1-13. Go to original source... Go to PubMed...
  28. Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a metaanalysis. BMJ 2005; 330: 342. Go to original source... Go to PubMed...
  29. Folsom AR, Anderson JP, Ross JA. Estrogen replacement therapy and ovarian cancer. Epidemiology 2004; 15: 100-104. Go to original source... Go to PubMed...
  30. Glud E, Kjaer SK, Thomsen BL, et al. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med, 2004; 164: 2253-2259. Go to original source... Go to PubMed...
  31. Lacey JV Jr, Brinton LA, Leitzmann MF, et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 2006; 4: 1397-1405. Go to original source... Go to PubMed...
  32. Moorman PG, Schildkraut JM, Calingaert B, et al. Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol 2005; 193: 76-82. Go to original source... Go to PubMed...
  33. Pike MC, Pearce CL, Peters R. Hormonal factors and the risk of invasive ovarian cancer: a population based case-control study. Fertil Steril 2004; 82: 186-195. Go to original source... Go to PubMed...
  34. Rodriguez C, Patel AV, Calle EE, et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285: 1460-1465. Go to original source... Go to PubMed...
  35. Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA, 2005; 293: 330-339. Go to original source... Go to PubMed...
  36. Nelson HD, Vesco K-K, Hanney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295: 2057-2071. Go to original source... Go to PubMed...
  37. Kronenberg F. Menopausal hot flashes: A review of physiology and biosociocultural perspective on methods of assessment. J Nutr 2010; 140: 1380S-1385S. Go to original source... Go to PubMed...
  38. Gaweesh S, Ewies AA. Folic acid supplementation cures hot flushes in postmenopausal women. Med Hypotheses, 2010; 74: 286-288. Go to original source... Go to PubMed...
  39. Mischoulon D, Raab MF. The role of folate in depression and dementia. J Clin Psychiatry 2007; 68: 28-33.
  40. Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: A systemic review to update the U.S. preventive services task force recommendations. Ann Intern Med 2012; 157: 1-10. Go to original source... Go to PubMed...
  41. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralowdose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 104: 443-451. Go to PubMed...
  42. Gabriel SR, Carmona L, Roque M, et al. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev, 2005; 18, CD002229. Go to original source... Go to PubMed...
  43. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465-1477. Go to original source... Go to PubMed...
  44. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present, and future in perspective. Climacteric 2012; 15: 217-228. Go to original source... Go to PubMed...
  45. Novella S, Dantas AP, Segarra G. Vascular aging in women: is estrogen the fountain of youth? Frontiers in Physiology 2012; 3: 1-8. Go to original source... Go to PubMed...
  46. Miller VM, Black DM, Brinton EA, et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2: 228-239.
  47. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, et al. Hot flashes and subclinical cardiovascular disease. Findings from Study of womens health across the nation heart study. Circulation 2008; 118: 1234-1240. Go to original source... Go to PubMed...
  48. Thurston RC, Christie IC, Mathews KA. Hot Flashes and cardiac vagal control: a link to cardiovascular risk? Menopause 2010; 17: 456-461. Go to original source... Go to PubMed...
  49. Lethaby AE, Brown J, Marjoribanks J, et al. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev, 2007, CD001395. Go to original source...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.